The drug development company backed by Ucyclyd, part of Medicis Pharmaceutical Corporation, is looking to raise the funds as it seeks Food and Drug Administration approval for its main product.
Hyperion Therapeutics, a US-based healthcare company backed by Ucyclyd, part of Medicis Pharmaceutical Corporation, filed on Friday for an up to $57.5m initial public offering.
The company develops drugs for treating orphan diseases and in the field of hepatology. The company’s main drug Ravicti treats urea cycle disorders and hepatic encephalopathy (the occurrence of a consciousness problem as a result of liver failure). It is looking to receive approval from US regulator Food and Drug Administration later this year.
…
